- Home
- EDRY vs GBIO Comparison
EDRY vs GBIO Comparison
Compare EDRY & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDRY
- GBIO
- Stock Information
- Founded
- EDRY 2018
- GBIO 2016
- Country
- EDRY Greece
- GBIO United States
- Employees
- EDRY N/A
- GBIO N/A
- Industry
- EDRY Marine Transportation
- GBIO Biotechnology: Pharmaceutical Preparations
- Sector
- EDRY Consumer Discretionary
- GBIO Health Care
- Exchange
- EDRY Nasdaq
- GBIO Nasdaq
- Market Cap
- EDRY 27.3M
- GBIO 29.5M
- IPO Year
- EDRY N/A
- GBIO 2020
- Fundamental
- Price
- EDRY $10.79
- GBIO $4.61
- Analyst Decision
- EDRY
- GBIO Strong Buy
- Analyst Count
- EDRY 0
- GBIO 4
- Target Price
- EDRY N/A
- GBIO $7.33
- AVG Volume (30 Days)
- EDRY 3.7K
- GBIO 248.9K
- Earning Date
- EDRY 08-07-2025
- GBIO 08-06-2025
- Dividend Yield
- EDRY N/A
- GBIO N/A
- EPS Growth
- EDRY N/A
- GBIO N/A
- EPS
- EDRY N/A
- GBIO N/A
- Revenue
- EDRY $55,867,583.00
- GBIO $24,556,000.00
- Revenue This Year
- EDRY N/A
- GBIO N/A
- Revenue Next Year
- EDRY $28.27
- GBIO N/A
- P/E Ratio
- EDRY N/A
- GBIO N/A
- Revenue Growth
- EDRY 10.25
- GBIO 146.47
- 52 Week Low
- EDRY $7.60
- GBIO $3.00
- 52 Week High
- EDRY $23.28
- GBIO $36.50
- Technical
- Relative Strength Index (RSI)
- EDRY 66.83
- GBIO 56.74
- Support Level
- EDRY $10.56
- GBIO $4.05
- Resistance Level
- EDRY $10.99
- GBIO $5.00
- Average True Range (ATR)
- EDRY 0.41
- GBIO 0.57
- MACD
- EDRY 0.05
- GBIO 0.04
- Stochastic Oscillator
- EDRY 79.38
- GBIO 50.38
About EDRY EuroDry Ltd.
EuroDry Ltd is a holding company. It is a provider of ocean-going transportation. The company owns and operates dry bulk carriers that transport bulk such as iron ore, coal, and grains, and minor bulks such as bauxite, phosphate, and fertilizers. It operates under one operating and one reportable segment, that of operating dry bulk vessels.
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable differentiated therapeutic applications. Its first platform is a potent, selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.